Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

OBJECTIVE: To evaluate apremilast treatment in patients with active psoriatic arthritis, including current skin involvement, despite prior therapy with conventional disease-modifying antirheumatic drugs and/or biologic agents. METHODS: Patients (N=505) were randomised (1:1:1) to placebo, apremilast...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Rheum Dis
Autors principals: Edwards, Christopher J, Blanco, Francisco J, Crowley, Jeffrey, Birbara, Charles A, Jaworski, Janusz, Aelion, Jacob, Stevens, Randall M, Vessey, Adele, Zhan, Xiaojiang, Bird, Paul
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2016
Matèries:
Clinical and Epidemiological Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4893110/
https://ncbi.nlm.nih.gov/pubmed/26792812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2015-207963
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars